SGCIA
Smith Graham & Co Investment Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $5.94M | Buy |
83,121
+21,272
| +34% | +$1.52M | 0.68% | 61 |
|
|
2023
Q3 | $3.71M | Sell |
61,849
-587
| -0.9% | -$35.2K | 0.46% | 109 |
|
|
2023
Q2 | $4.5M | Sell |
62,436
-2,727
| -4% | -$197K | 0.54% | 87 |
|
|
2023
Q1 | $4.79M | Sell |
65,163
-209
| -0.3% | -$15.4K | 0.58% | 80 |
|
|
2022
Q4 | $4.37M | Sell |
65,372
-20,485
| -24% | -$1.37M | 0.53% | 90 |
|
|
2022
Q3 | $7.39M | Sell |
85,857
-118
| -0.1% | -$10.2K | 0.98% | 27 |
|
|
2022
Q2 | $7.67M | Sell |
85,975
-859
| -1% | -$76.6K | 0.95% | 32 |
|
|
2022
Q1 | $9.77M | Sell |
86,834
-558
| -0.6% | -$62.8K | 1.01% | 24 |
|
|
2021
Q4 | $13.5M | Sell |
87,392
-7,051
| -7% | -$1.09M | 1.34% | 9 |
|
|
2021
Q3 | $13.2M | Sell |
94,443
-3,945
| -4% | -$550K | 1.32% | 12 |
|
|
2021
Q2 | $12.9M | Sell |
98,388
-3,511
| -3% | -$461K | 1.14% | 18 |
|
|
2021
Q1 | $15.5M | Buy |
101,899
+4,357
| +4% | +$664K | 1.26% | 13 |
|
|
2020
Q4 | $9.7M | Buy |
97,542
+23,813
| +32% | +$2.37M | 0.89% | 34 |
|
|
2020
Q3 | $7.03M | Buy |
+73,729
| New | +$7.03M | 0.8% | 46 |
|